NEW YORK (GenomeWeb News) – Clinical lab firm Quest Diagnostics said Friday that the US Food and Drug Administration has issued a second emergency use authorization for a 2009 H1N1 flu test made by its Focus Diagnostics subsidiary.

Quest said that the new EUA allows Focus to market and offer its Simplexa Influenza A H1N1 (2009) test for use on 3M's Integrated Cycler to CLIA high-complexity laboratories for the duration of the emergency period. 3M's system is a microfluidic molecular diagnostic testing system that is not yet cleared by the FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.